Stryker (SYK)
(Delayed Data from NYSE)
$369.02 USD
-0.84 (-0.23%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $369.15 +0.13 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$369.02 USD
-0.84 (-0.23%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $369.15 +0.13 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum D VGM
Zacks News
Boston Scientific Stock Gains From Market Expansion, Innovation
by Zacks Equity Research
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
Stryker Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
SYK's third-quarter results reflect strong segmental performance, along with a rise in operating margin.
Here's What Key Metrics Tell Us About Stryker (SYK) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stryker (SYK) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 3.24% and 2.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Strong Segmental Performance to Drive Stryker's Q3 Earnings
by Zacks Equity Research
SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Insights Into Stryker (SYK) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Stryker (SYK) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
GE HealthCare Acquires Intelligent Ultrasound's Clinical AI Business
by Zacks Equity Research
GEHC acquires clinical AI business to aid its ultrasound portfolio with AI-driven image analysis tools.
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
by Zacks Equity Research
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
Globus Medical Expands Orthopedic Trauma Portfolio With New Launches
by Zacks Equity Research
GMED launches ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments and CAPTIVATE SOLA Headless Screws.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
PBH vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?
by Zacks Equity Research
Styker's flagship, Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
SYK Stock May Gain From Completion of Vertos Medical Acquisition
by Zacks Equity Research
Stryker completes the acquisition of Vertos Medical to expand its interventional pain management solutions.
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Stryker Shares May Gain on the Completion of the Acquisition of NICO
by Zacks Equity Research
SYK completes the acquisition of NICO to strengthen its portfolio of solutions for tumor resection and the treatment of ICH.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Stryker Stock Declines Despite Completion of care.ai Acquisition
by Zacks Equity Research
SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.
Here's How Much a $1000 Investment in Stryker Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio
by Zacks Equity Research
Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Why Is Stryker (SYK) Up 8.8% Since Last Earnings Report?
by Zacks Equity Research
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker Rallies 19.8% Year to Date: What's Driving the Stock?
by Zacks Equity Research
SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
If You Invested $1000 in Stryker a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
The Zacks Analyst Blog Toyota Motor, IBM, Stryker and Fossil Group
by Zacks Equity Research
Toyota Motor, IBM, Stryker and Fossil Group are included in this Analyst Blog.